Roche Nutley

Manufacturing makes a comeback at Roche’s Nutley site

pharmafile | October 4, 2011 | News story | Manufacturing and Production Roche, pharma manufacturing news 

Roche has opened a new manufacturing facility at its campus in Nutley, New Jersey, that will supply dosage forms for its early- to mid-stage clinical trials programmes.

The announcement late last week is a boost for the 127-acre Nutley site, which has seen its workforce slashed in recent months as part of a company-wide cost-reduction programme at the pharmaceutical heavyweight.

Announced in November 2010, the restructuring was designed to cut worker numbers across the group by 4,800 (around 6%), with Nutley losing more than 1,000 out of its total of 2,400 staff. Most of the reductions stemmed from Roche’s decision to shift commercial-scale manufacturing operations located there to California, although a number of R&D programmes were also discontinued at the site.

“This is a vitally important milestone for the Nutley site as well as pharmaceutical research and early development at Roche,” commented Waseem Malick, the firm’s vice president of pharmaceutical and analytical R&D.

“It enables continued support of our portfolio, and is another example of Roche’s commitment to Nutley as a major research centre for Roche,” he added. Nutley is one of the main centres in Roche’s R&D network, focusing on oncology, inflammation and virology.

The new manufacturing unit covers some 17,000 sq.ft. and will specialise in the production of dosage forms containing high-potency active pharmaceutical ingredients (HPAPIs). It will operate at a scale sufficient to provide materials for preclinical, Phase I and Phase II testing.

The plant opened just over a year after construction began in August 2010, and can produce tablets, capsules, powders, suspensions and solutions, said Roche.

In addition to multipurpose isolation suites for manufacturing the dosage forms, the new plant also houses warehousing and mechanical rooms.

Phil Taylor

Related Content

Roche’s Vabysmo approved by FDA for retinal vein occlusion treatment

Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (farcimab) …

Roche announces acquisition of Telavant

Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, …

EC approves Roche’s Evrysdi for babies under two months with SMA

Roche has announced that the European Commission (EC) has approved the extension of Evrysdi’s marketing …

Latest content